NCT03500159 - Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 18, 2018

Primary Completion Date

July 17, 2018

Study Completion Date

July 17, 2018

Conditions

Chronic ProstatitisChronic Pelvic Pain Syndrome

Interventions

DRUG

AQX-1125 200 mg

Synthetic SHIP1 activator

DRUG

Placebo

Appearance and weight matched tablets without the active product ingredient

Trial Locations (27)

11042

Site 1009, Lake Success

19140

Site 1007, Philadelphia

27612

Site 1008, Raleigh

28207

Site 1021, Charlotte

28401

Site 1019, Wilmington

34653

Site 1027, New Port Richey

35209

Site 1026, Homewood

36608

Site 1010, Mobile

44195

Site 1001, Cleveland

47130

Site 1023, Jeffersonville

48072

Site 1002, Royal Oak

50266

Site 1014, West Des Moines

62769

Site 1015, Springfield

71106

Site 1012, Shreveport

73120

Site 1017, Oklahoma City

75231

Site 1022, Dallas

83814

Site 1013, Coeur d'Alene

85710

Site 1004, Tucson

87109

Site 1011, Albuquerque

90048

Site 1016, Los Angeles

Site 1020, Los Angeles

90720

Site 1018, Los Alamitos

92653

Site 1028, Laguna Hills

L6T 4S5

Site 1005, Brampton

K7L 3J7

Site 1025, Kingston

L6H 3P1

Site 1003, Oakville

M6A 3B5

Site 1024, Toronto